SEC Company Response from REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589) (REGN) — Aug 4, 2016
REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589)
Date: Aug. 4, 2016 · CIK: 0000872589 · Accession: 0001532176-16-000069
AI Filing Summary & Sentiment
File numbers found in text: 000-19034
Referenced dates: July 29, 2016
Letter
Via EDGAR Office of Healthcare and Insurance Division of Corporation Finance Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed February 11, 2016 File No. 000-19034
Dear Mr. Rosenberg:
Regeneron Pharmaceuticals, Inc. (the "Company") acknowledges receipt of the letter dated July 29, 2016 provided by the staff of the Securities and Exchange Commission (the "Staff") with respect to the above-referenced Form 10-K. The Company subsequently corresponded with Bonnie Baynes of the Staff on August 3, 2016, who kindly granted the Company’s request for a five business day extension. Accordingly, the Company plans to provide its response to the letter on or before August 19, 2016.
If you have any questions regarding the foregoing, please contact me at (914) 847-7270.
Very truly yours,
REGENERON PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm Document Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com Via EDGAR August 4, 2016 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Office of Healthcare and Insurance U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed February 11, 2016 File No. 000-19034 Dear Mr. Rosenberg: Regeneron Pharmaceuticals, Inc. (the "Company") acknowledges receipt of the letter dated July 29, 2016 provided by the staff of the Securities and Exchange Commission (the "Staff") with respect to the above-referenced Form 10-K. The Company subsequently corresponded with Bonnie Baynes of the Staff on August 3, 2016, who kindly granted the Company’s request for a five business day extension. Accordingly, the Company plans to provide its response to the letter on or before August 19, 2016. If you have any questions regarding the foregoing, please contact me at (914) 847-7270. Very truly yours, REGENERON PHARMACEUTICALS, INC. /s/ Robert E. Landry Robert E. Landry Senior Vice President, Finance and Chief Financial Officer cc: Bonnie Baynes, Staff Accountant